Abstract: Provided herein are isolated nucleic acids comprising two or more nucleotide sequences capable of encoding genome-editing enzymes. Also provided are vectors comprising the isolated nucleic acids, host cells comprising the vectors, and kits comprising the isolated nucleic acids.

Abstract: In one embodiment, a character engine models a character that interacts with users. The character engine receives user input data from a user device, and analyzes the user input data to determine a user intent and an assessment domain. Subsequently, the character engine selects inference algorithm(s) that include machine learning capabilities based on the intent and the assessment domain. The character engine computes a response to the user input data based on the selected inference algorithm(s) and a set of personality characteristics that are associated with the character. Finally, the character engine causes the user device to output the response to the user. In this fashion, the character engine includes sensing functionality, thinking and learning functionality, and expressing functionality.

Abstract: In one embodiment, a character engine models a character that interacts with users. The character engine receives user input data from a user device, and analyzes the user input data to determine a user intent and an assessment domain. Subsequently, the character engine selects inference algorithm(s) that include machine learning capabilities based on the intent and the assessment domain. The character engine computes a response to the user input data based on the selected inference algorithm(s) and a set of personality characteristics that are associated with the character. Finally, the character engine causes the user device to output the response to the user. In this fashion, the character engine includes sensing functionality, thinking and learning functionality, and expressing functionality.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: A trocar or surgical port assembly includes an annular body attachable to a patient at an incision in a patient. The annular body includes a cylindrical insert portion defining a proximal end and a distal end and a flange disposed at the proximal end of the cylindrical insert portion. A skirt is attached to the distal end of the cylindrical insert portion and extends distally from the annular body and includes a flexible web and a wire attached to the flexible web that in a multiple looped configuration of non-intersecting curved portions positioned in the vicinity of the distal portion of the skirt to enable the flexible web to be biased via a biasing force exerted by the wire into a funnel-shaped open configuration having an opening of the skirt at the distal portion of the skirt that is larger than an opening of the skirt at the proximal portion.

Abstract: A surgical port comprising a body and first and second cannula extending from the body and movable with respect to the body via an instrument inserted through the respective cannula. The cannulas can extend distally from the body and can include one or more seals. A port assembly and first and second instruments manipulatable in a crossed configuration are also disclosed.

Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.

Abstract: A surgical port comprising a body and first and second cannula extending from the body and movable with respect to the body via an instrument inserted through the respective cannula. The cannulas can extend distally from the body and can include one or more seals. A port assembly and first and second instruments manipulatable in a crossed configuration are also disclosed.

Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.

Abstract: A surgical port comprising a body and first and second cannula extending from the body and movable with respect to the body via an instrument inserted through the respective cannula. The cannulas can extend distally from the body and can include one or more seals. A port assembly and first and second instruments manipulatable in a crossed configuration are also disclosed.

Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.

Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.

Abstract: Various embodiments of a laparoscopic trocar assembly are disclosed. The port assemblies include inserted parts that protect the patient's tissues at the point of deployment. The port assemblies include seals for maintaining pneumoperitoneum both when instrument are being used and when instruments are not inserted.

Abstract: A medical instrument insertable through a cannula, the instrument comprising an elongate shaft; and an operative tip having a first jaw and a second jaw movable with respect to the first jaw. The operative tip disposed at a distal end of said elongate shaft and being disposed on said shaft for rotation relative to at least a distal end portion of said shaft about a longitudinal axis of said distal end portion.

Abstract: A medical instrument insertable through a cannula, the instrument comprising an elongate shaft; and an operative tip having a first jaw and a second jaw movable with respect to the first jaw. The operative tip disposed at a distal end of said elongate shaft and being disposed on said shaft for rotation relative to at least a distal end portion of said shaft about a longitudinal axis of said distal end portion.